Alevin’s preclinical pipeline features small molecules that target integrin receptors.
Our broad intellectual property estate contains an array of inhibitors that are both potent and isoform-selective.
A potent and selective inhibitor of the αvβ6 integrin under development as an inhaled drug treatment for idiopathic pulmonary fibrosis
A pan-integrin inhibitor, under development as an oral drug to treat liver and kidney fibrosis, and cancer
We have multiple additional isoform-selective inhibitor programmes under development.